LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that results presented at the International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer showed that ganetespib (STA-9090) is more potent than 17-AAG and is synergistic with doxorubicin in a model of small cell lung cancer. Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) currently being studied in a broad range of clinical trials with approximately 400 patients treated to date. Ganetespib is structurally unrelated to first-generation, ansamycin-family Hsp90 inhibitors such as 17-AAG or IPI-504.
